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Abstract
VP51 and VP76 are two structural proteins of white spot syndrome virus (WSSV). However, there
is some controversy about their localization in the virion at present. In this study, we employ
multiple approaches to reevaluate the location of VP51 and VP76. Firstly, we found VP51 and VP76
presence in viral nucleocapsids fraction by Western blotting. Secondly, after the high-salt treatment
of nucleocapsids, VP51 and VP76 were still exclusively present in viral capsids by Western blotting
and immunoelectron microscopy, suggesting two proteins are structural components of the viral
capsid. To gather more evidence, we developed a method based on immunofluorescence flow
cytometry. The results revealed that the mean fluorescence intensity of the viral capsids group was
significantly higher than that of intact virions group after incubation with anti-VP51 or anti-VP76
serum and fluorescein isothiocyanate conjugated secondary antibody. All these results indicate that
VP51 and VP76 are both capsid proteins of WSSV.
Background
White spot syndrome virus (WSSV), the only species of
the genus Whispovirus of the family Nimaviridae, is one of
most virulent viral disease known in the shrimp farming
industry around the world, which also infect most species
of crustacean, such as crabs and crayfish [1-3]. Studies
have shown that WSSV virion is an ellipsoid shape envel-
oped particle and it has a bacilliform nucleocapsid which
is similar to insert baculovirus. The most obvious feature
of WSSV is the presence of a long, tail-like extension at
one end of the virion [4-9].
Up to now, the complete genome sequences of three iso-
lates (WSSV-CN, WSSV-TH and WSSV-TW) have been
sequenced [10-12] and many structural proteins of WSSV
have been identified by combining SDS-PAGE with mass
spectrometry (MS) or two-dimensional electrophoresis
with MS [13-15], some of which have been confirmed to
be envelope proteins by Western blotting and immunoe-
lectron microscopy (IEM) including: VP24 [16], VP26/
P22 [16,17], VP28 [18], VP31 [19], VP36/VP281 [20],
VP39 [21], VP124 [22], VP187 [23] and VP110 [24]. How-
ever, the nucleocapsid proteins of WSSV are less well
understood, except VP15 and VP664. VP15 is a basic DNA
binding protein located in WSSV nucleocapsid and simi-
lar to histone [25,26]. VP664, the largest protein of WSSV,
containing 6077 aa, was reported to encode a major
nucleocapsid protein VP664 [27].
Recently, we noticed that two WSSV structural proteins,
VP51 and VP76, seemed to be present in viral nucleocap-
sid fraction [28]. In addition, VP51 was also thought to be
viral nucleocapsid proteins by immunoblotting in recent
study [29]. However, in previous studies, VP51 and VP76
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were reported as viral envelope proteins. VP51 was con-
sidered as a viral envelope protein by IEM after 18 struc-
tural proteins from the virions using MS were identified
[13]. Likewise, VP76 was believed as viral envelope pro-
tein by Western blotting [30]. Because the localization of
the two proteins is controversial at present, a more precise
identification is necessary to perform functional studies in
future. In this investigation, we employ multiple
approaches to clarify the location of VP51 and VP76, and
all experimental evidence indicated that VP51 and VP76
are viral capsid proteins.
Results and discussion
Identification of VP51 and VP76 by Western blotting
The truncated recombinant proteins, VP51p and VP76p,
were expressed in Escherichia coli and purified by using Ni-
NTA affinity chromatography, and then specific antise-
rum against VP51 and VP76 were obtained by immuniz-
ing mice. To perform localization studies, WSSV virions,
envelope and nucleocapsid fractions were separated by
SDS-PAGE, followed by staining with Coomassie brilliant
blue R-250. As shown in Fig. 1a, at least 8 distinct protein
bands were revealed from the viral nucleocapsid fraction,
a. Coomassie brilliant blue-stained 12% SDS-PAGE of the various fractions of WSSV Figure 1
a. Coomassie brilliant blue-stained 12% SDS-PAGE of the various fractions of WSSV. Lanes: M, low molecular mass protein 
marker; V, intact virsions; E, envelope fraction after Triton X-100 treatment; N, nucleocapsid fraction after Triton X-100 treat-
ment. VP51 and VP76 are indicated by arrows. b. Western blot analysis with anti-VP51 or VP76 serum respectively. Lanes: E, 
envelope fraction after Triton X-100 treatment; N, nucleocapsid fraction after Triton X-100 treatment. VP51 and VP76 are 
indicated by arrows.Virology Journal 2006, 3:76 http://www.virologyj.com/content/3/1/76
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including two of them with apparent molecular mass of
about 51 and 76 kDa. Whilst, Western blotting analysis
indicated that the two proteins were exclusively detected
in nucleocapsid fraction (Fig. 1b).
To eliminate the possible interference of the remaining
viral envelope proteins, Triton-treated nucleocapsids were
further treated under more stringent conditions (high-salt
or low-pH). The results of SDS-PAGE analysis shown the
protein bands of 51 and 76 kDa were still observed clearly
after high-salt or low-pH treatment (Fig. 2a), whilst West-
ern blot analysis also revealed the same results using anti-
VP51 or VP76 serum (Fig. 2b, c, line1, 2 and 4). Above
results suggest that VP51 and VP76 are associated with
virus nucleocapsids.
In addition, during high-salt treatment, we observed that
the nucleocapsid suspension became very thick in com-
parison with the result of low-pH treatment, and VP15
was completely removed from viral nucleocapsid fraction
after the treatment (Fig. 2a, lane 1), but TEM results
showed that high-salt treated sample still retained its inte-
grality in configuration (Fig. 2d). Therefore, we conclude
that high-salt treatment can lead to release of viral
genomic DNA fibres and VP15 from viral nucleocapsid
particles, and so the image of particles observed under
electron microscope actually is viral capsids. The above
experiments indicated that VP51 and VP76 are likely the
viral minor capsid proteins, suggesting that WSSV capsid
particles can be purified by high-salt treatment of nucleo-
capsids.
Localization of VP51 and VP76 by IEM
To verify above results, we performed immunoelectron
microscopy localization studies by means of an indirect
immunogold labelling method using anti-VP51 or VP76
antibodies. The results showed that no gold particles
could be seen on purified WSSV virions when using anti-
VP51 or anti-VP76 serum as the primary antibody (Fig.
3a), whereas under same condition, gold particles were
markedly distributed on high-salt treated nucleocapsids,
viz. capsids (Fig. 3c, d). Control experiments showed that
no gold particles were found on the capsids when using
non-immune mouse serum as the primary antibody (Fig.
3b). The IEM results indicated that VP51 and VP76 were
located on the viral capsid, suggesting that they are struc-
tural components of the viral capsid.
Localization of VP51 and VP76 by FCM
It is well known that FCM could be used to analyze cell
surface marker by means of a fluorescent labeled specific
antibody. In order to gather more evidence to make a
credible conclusion, we developed a practical method
based on immunofluorescence flow cytometry to study
the localization of VP51 and VP76 by comparing the
mean fluorescence intensity of the population of intact
virions or high-salt treated nucleocapsids (capsids). This
notion derives from reports that virus particles could be
counted directly by FCM, such as the quantification of
marine viruses [31,32] and the detection of baculovirus
[33-35]. Although WSSV is small relatively in size in com-
parison with cells, their size (virion: ~ 275 × 120 nm;
nucleocapsid: ~ 300 × 70 nm, [9]) is enough to be
detected by FCM. In this experiment, WSSV virion and
capsid groups were incubated with anti-VP51 or anti-
VP76 serum, followed by staining with FITC-conjugated
goat anti-mouse IgG. The analysis results showed that the
fluorescent signal of the viral capsid group was signifi-
cantly higher than the virion group (Fig. 4). To ensure reli-
ability of data, anti-VP664 or anti-VP28 serum was
conducted as primary antibody in positive control experi-
ments. As expected, a stronger fluorescent signal was
observed in the capsid group of anti-VP664 serum treat-
ment, whereas the fluorescence intensity from virion
group was low, which only corresponded to the back-
ground signal caused by pre-immune serum. In contrast,
the virion group displayed much strong fluorescence
intensity by using anti-VP28 serum. This data further sup-
port the conclusion from Western blotting or IEM. Based
on the experiment, we considered FCM is an effective
alternative technique for the localization of the structural
proteins of WSSV or other large viruses due to its facility,
high efficiency and sensitivity.
All in all, WSSV is most virulent pathogen of the penaeid
shrimp farming industry. But until now, the pathogenesis
of WSSV has not been clearly understood on the molecu-
lar level. Thus there is an urgent need to study the struc-
tural proteins and their function of this virus to find out
the solution to prevent or cure this disease. In this paper,
we performed localization studies of two viral structural
proteins, VP51 and VP76, in WSSV virions by employing
multiple approaches, and make a definite conclusion, i.e.
VP51 and VP76 reside in the viral nucleocapsid, and are
viral minor capsid proteins. The results may facilitate a
better understanding of the molecular mechanism of
WSSV infection and assembly, or be helpful for the con-
trol of virus infection in the future.
Conclusion
The localization of the two proteins, VP51 and VP76, is
controversial at present. In this investigation, we employ
multiple approaches (Western blotting and IEM, as well as
flow cytometry etc.) to clarify the location of VP51 and
VP76, and all experimental evidence indicated that VP51
and VP76 reside in the viral nucleocapsid, and are viral
minor capsid proteins. We considered FCM is an effective
alternative technique for the localization of the structural
proteins of WSSV or other large viruses due to its facility,
efficiency and sensitivity.Virology Journal 2006, 3:76 http://www.virologyj.com/content/3/1/76
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a. Coomassie brilliant blue-stained 12% SDS-PAGE of the nucleocapsid and envelope proteins of WSSV Figure 2
a. Coomassie brilliant blue-stained 12% SDS-PAGE of the nucleocapsid and envelope proteins of WSSV. Lanes: M, low molecu-
lar mass protein marker; 1, high-salt treated nucleocapsid sample; 2, low-pH treated nucleocapsid sample. b, c. Western blot 
analysis with anti-VP51 or VP76 serum respectively. 1, high-salt treated nucleocapsid sample; 2, low-pH treated nucleocapsid 
sample; 3, envelope fraction after Triton X-100 treatment; 4, nucleocapsid fraction after Triton X-100 treatment. d, e. TEM 
examination of high-salt or low-pH treated nucleocapsid sample, respectively. Bars, 100 nm.Virology Journal 2006, 3:76 http://www.virologyj.com/content/3/1/76
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Localization of VP51 and VP76 in WSSV by IEM Figure 3
Localization of VP51 and VP76 in WSSV by IEM. (a) Intact virions with anti-VP51 or anti-VP76 serum; (b) high-salt treated 
nucleocapsid sample with non-immune mouse serum; (c) high-salt treated nucleocapsid sample with anti-VP51 serum; (d) high-
salt treated nucleocapsid sample with anti-VP76 serum. Bars, 100 nm.Virology Journal 2006, 3:76 http://www.virologyj.com/content/3/1/76
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Materials and methods
Preparation of intact WSSV virions and nucleocapsids
WSSV virions were prepared essentially as described previ-
ously [28]. Briefly, WSSV-infected crayfish tissues were
homogenized, and then centrifuged at 3500 × g for 5 min
at 4°C. After filtering by nylon net (400 mesh), the super-
natant was centrifuged at 30,000 × g for 30 min at 4°C.
Then, the upper loose layer (pink) of pellet was rinsed out
carefully using a Pasteur pipette, and the lower compact
layer (gray) was resuspended in TM buffer (50 mM Tris-
HCl/pH7.5, 10 mM MgCl2). After several rounds of con-
ventional differential centrifugations, the milk-like pure
virus suspension was obtained and stored at 4°C until
use.
Separation of envelope and nucleocapsid fractions was
carried out as described recently with slight modifications
[16]. In brief, a 0.5 ml pure virus suspension was mixed
with an equal volume of 2% Triton X-100 and then incu-
bated for 30 min at room temperature with gentle shak-
ing. The nucleocapsids were purified by centrifugation at
20,000 × g for 20 min at 4°C. The envelope proteins (the
supernatant) were collected and used for the following
experiments, whilst the pellet (nucleocapsids) was sub-
jected to a second round of Triton X-100 extraction to
ensure complete treatment. Finally, the Triton-treated
nucleocapsids were suspended in 1 ml of TM buffer and
stored at 4°C until use.
Retreatment of nucleocapsids by high-salt or low-pH 
buffer
High-salt treatment: in general, a 0.2 ml Triton-treated
nucleocapsid suspension was mixed with 0.8 ml of TNK
buffer (20 mM Tris-HCl/pH7.6, 0.8 M NaCl, 0.8 M KCl),
and mixture incubated for 30 min at 4°C. The mucous
mixture was centrifuged at 50,000 × g for 20 min at 4°C.
Then the supernatant was discarded, and the insoluble
fraction was retreated twice in TNK buffer as described
above to remove any nonspecific binding proteins. Final,
the high-salt treated sample was suspended in 0.2 ml of
TM buffer.
Low-pH treatment: Briefly, a 0.2 ml Triton-treated nucle-
ocapsid suspension was centrifuged at 15,000 × g for 10
min at 4°C. The pellet was suspended in 0.5 ml of 0.1 M
Glycine-HCl/pH 2.5 buffer by gently pipetting up and
Comparison of mean fluorescence intensity between WSSV capsid group (high-salt treated) and virion group stained with dif- ferent antiserum (in order: non-immune mouse, anti-VP28, anti-VP51, anti-VP76 and anti-VP664 serum) by immunofluores- cence flow cytometry Figure 4
Comparison of mean fluorescence intensity between WSSV capsid group (high-salt treated) and virion group stained with dif-
ferent antiserum (in order: non-immune mouse, anti-VP28, anti-VP51, anti-VP76 and anti-VP664 serum) by immunofluores-
cence flow cytometry. Data are expressed as the means ± standard deviation of three independent experiments.Virology Journal 2006, 3:76 http://www.virologyj.com/content/3/1/76
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down. This process was repeated once to remove any
remaining bound proteins. The low-pH treated sample
was suspended in 0.2 ml of TM buffer.
Expression and purification of proteins
VP51 and VP76 are the products of ORF wsv308 and
wsv220 of WSSV (GeneBank accession no. AF332093) and
composed of 466 and 674 amino acid residues, respec-
tively. To prepare the specific antibodies against VP51 and
VP76, a region of VP51 between amino acids 127 and 338
(212 amino acids, designated VP51p) and VP76 between
amino acids 253 and 510 (258 amino acids, designated
VP76p) were chosen for expression. The vp51p and vp76p
were amplified from the genomic DNA of WSSV using the
specific primers containing BamH  I and EcoR  I sites
(underlined): 5'-GCAGGATCCAGTTTGTCCGGTGCG-
TAC-3'/5'-GCAGAATTCTGTTTCCTCAGCAGAACG-3'
and 5'-GCAGGATCCGGCGATGATTCTGTAGATG-3'/5'-
GCAGAATTCAGTACGTGCCCAACAAGC-3'. PCR prod-
ucts were digested with corresponding restriction
endounclease and cloned into vector pET-His upstream of
a 6-His tag (Gene Power Laboratory Ltd). The recom-
binant plasmids pET-VP51p and pET-VP76p were trans-
formed into Escherichia coli strain BL21 (DE3) competent
cells and confirmed by sequencing. For proteins expres-
sion, bacteria were cultured until the OD600 reached ~
0.6, and induced with 0.4 mM isopropylthiogalactoside
for 6 h at 37°C, then harvested by centrifugation.and. His-
tagged recombinant proteins VP51p and VP76p were
purified by using Ni-NTA metal-affinity chromatography
under denaturing conditions according to the instructions
of QIAexpressionist system (Qiagen).
Antibody preparation and Western blot analysis
A polyclonal antiserum was prepared with purified
recombinant protein by immunizing mice four times,
each with an interval of 10 days. The antigen (~ 20 μg) was
mixed and emulsified with an equal volume of Freund's
complete adjuvant (Sigma), and then the emulsion was
injected intradermally into mouse. Subsequent three
injections were given using antigen emulsified with an
equal volume of Freund's incomplete adjuvant (Sigma).
Four days after the last injection, mice were exsanguin-
ated, serum was collected and the titers of antibody were
determined by enzyme-linked immunosorbent assay.
Specific antiserum of high titer was stored in aliquots at -
80°C until analyzed.
Protein samples from WSSV were subjected to SDS-PAGE
in 12% gels and transblotted onto polyvinylidene fluoride
membrane (Amersham Biosciences) by semi-dry blotting
at a constant current of 0.5 mA cm-2 for 1.5 h at room tem-
perature. The membrane was immersed in blocking buffer
(20 mM Tris-HCl/pH7.5, 150 mM NaCl, 3% BSA, 0.05%
Tween-20) at room temperature for 1 h, followed by incu-
bation with the specific antiserum (diluted 1:1000) in
blocking buffer at 4°C overnight. Subsequently, a second-
ary antibody, alkaline phosphatase-conjugated goat anti-
mouse IgG (Promega) was added at a dilution of 1:7500
in blocking buffer at 25°C for 1 h, and then signals were
detected by a detection solution (50 mM Tris-HCl/pH 9.5,
100 mM NaCl, 5 mM MgCl2) containing NBT/BCIP
(Roche).
Immunoelectron microscopy (IEM)
WSSV virions or high-salt treated nucleocapsids were
mounted on formvar-carbon-coated nickel grids grids
(300-mesh) and incubated for 1 h at room temperature.
After washing with PBS, the grids were blocked with 3%
BSA in PBS for 1 h, followed by incubation with anti-VP51
or anti-VP76 serum (diluted 1: 200 in 3% BSA) for 2 h.
After washing four times with PBS, grids were incubated
with goat anti-mouse IgG conjugated to colloidal gold (10
nm; Sigma) for 1 h. Subsequently, grids were washed four
times with PBS and briefly stained with 2% phosphotung-
stic acid (pH 7.0) for 20 min. Specimens were examined
by TEM (JEOL 100 cxII). For control experiment, primary
antibody was replaced with non-immune mouse serum
and treated as above.
Flow cytometry
A 0.2 ml WSSV virions or high-salt treated nucleocapsids
were mixed with an equal volume of blocking buffer (50
mM Tris-HCl/pH7.5, 100 mM NaCl, 10 mM MgCl2, 3%
BSA) and incubated for 30 min at room temperature, fol-
lowed by incubation with anti-VP51 or anti-VP76 serum
(diluted 1: 1000) for 1 h. Subsequently, the mixture was
sedimented at 12,000 × g for 10 min. The pellets were
washed thrice and resuspended in blocking buffer and
incubated with fluorescein isothiocyanate (FITC)-conju-
gated goat anti-mouse IgG (diluted 1:1000) for 1 h, fol-
lowed by centrifugation at 120,00 × g for 20 min, and
then the pellets washed thrice with PBS and resuspension
in 2 ml PBS. In order to validate the feasibility of the
method, VP28 (known high-abundant envelope protein)
or VP664 (known major nucleocapsid protein) was cho-
sen as positive control. Anti-VP28 or anti-VP664 serum
prepared in our laboratory (unpublished data) was used
as primary antibody, whilst non-immune mouse serum
was served as blank control. FITC-stained specimens were
analyzed by flow cytometry (FACSCalibur®; Becton Dick-
inson) and fluorescence intensity was determined for each
of the treatment groups. A total of 100,000 particles were
analyzed in each experiment and the data are expression
as the mean ± standard deviation of three independent
experiments.
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